Compare SACH & MIRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SACH | MIRA |
|---|---|---|
| Founded | 2010 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 38.4M | 32.1M |
| IPO Year | 2016 | 2023 |
| Metric | SACH | MIRA |
|---|---|---|
| Price | $0.99 | $0.75 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $2.00 | N/A |
| AVG Volume (30 Days) | 160.4K | ★ 1.6M |
| Earning Date | 05-06-2026 | 05-13-2026 |
| Dividend Yield | ★ 19.23% | N/A |
| EPS Growth | ★ 104.30 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $57,500,000.00 | N/A |
| Revenue This Year | $145.00 | N/A |
| Revenue Next Year | $6.80 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.76 | $0.60 |
| 52 Week High | $1.45 | $2.45 |
| Indicator | SACH | MIRA |
|---|---|---|
| Relative Strength Index (RSI) | 66.41 | 46.82 |
| Support Level | $0.91 | $0.72 |
| Resistance Level | $0.98 | $0.82 |
| Average True Range (ATR) | 0.03 | 0.08 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 77.99 | 11.72 |
Sachem Capital Corp is a real estate investment trust. The company specializes in originating, underwriting, funding, servicing, and managing a portfolio of short-term loans secured by first mortgage liens on real property located in Connecticut. Its primary objective is to grow the loan portfolio while protecting and preserving capital in a manner that provides for attractive risk-adjusted returns to shareholders over the long term through dividends. The company earns the majority of its revenue through Interest income from loans.
Mira Pharmaceuticals Inc is a clinical-stage pharmaceutical development company focused on developing novel oral small-molecule therapeutics for neurologic, neuropsychiatric, metabolic, and inflammatory disorders. The company's pipeline includes three product candidates: Ketamir-2, MIRA-55, and SKNY-1, three drug candidates designed to address unmet medical needs across neuropathic and inflammatory pain, central nervous system disorders, and metabolic and behavioral conditions. The company operates as a single operating and reportable segment.